Overall verdict
Neutral
3.8/10
1-year performance
+0.26%
Score breakdown
Up 0.3% over 1 year, 18% of the 52-week range.
Strongest: Growth 10.0/10. Weakest: Shareholder return 0.0/10.
10 analysts, target +1.7% vs the price.
Camp4 Therapeutics Corporation, a clinical-stage biopharmaceutical company, discovers and develops RNA-based therapeutics to treat a range of genetic diseases. Its lead product candidate is CMP-001, which is in a Phase 1/2 clinical trial for the treatment of urea cycle disorders. The company also develops CMP-002 for the treatment of SYNGAP1-related disorders.
Camp4 Therapeutics Corporation was formerly known as Marauder Therapeutics, Inc. and changed its name to Camp4 Therapeutics Corporation in March 2018. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Sector
Health Care
Industry
Biotechnology
Primary listing
Nasdaq
United States
CEO
Joshua Mandel-Brehm
Founded
2015
Employees
48
Revenue / employee
72 875 USD
Next earnings
March 5, 2027 (estimated)
Institutional holders
- FMR LLC7.82%
- BlackRock, Inc.3.19%
- GEODE CAPITAL MANAGEMENT, LLC1.44%
- STATE STREET CORP0.89%
- GOLDMAN SACHS GROUP INC0.29%
- Bank of New York Mellon Corp0.14%
- MORGAN STANLEY0.02%
- JPMORGAN CHASE & CO0.02%
- Rest of the register86.18%
8 13F filings as of September 30, 2026: US managers above $100M, filed up to 45 days after quarter end. No insiders, no retail. A share on loan is declared by its lender and by whoever bought it from the short seller, so the total can exceed 100%.
Research uses the underlying stock’s market history. The purchase quote is calculated separately when you review your order.
52-week high
7.75 USD
52-week low
2.90 USD
1-year performance
0.26%
Rising
Year-to-date performance
-39.07%
Rising
Drawdown
-51.10%
Major drawdown
Position in the 52-week range
18% of range
Gross margin 64.0%, the company loses 2276.3% of its revenue, ROIC -139.5%, ROE -146.1%.
Net margin
-2276.33%
Negative
Sector -212.24%|S&P 13.35%
Gross margin
64.00%
Exceptional
Return on equity (ROE)
-146.12%
Negative
Sector -55.30%|S&P 16.98%
Return on invested capital (ROIC)
-139.45%
Negative
Free cash flow margin (FCF)
-496.39%
Negative
Revenue to net income
Growth
10.0/10Revenue up 138.9% over 1 year.
Revenue (trailing 12 months)
5.3M USD
Revenue growth (1y)
138.87%
Hyper-growth
Revenue growth (3y)
—
EPS growth (1y)
—
EPS CAGR (5y)
—
EPS revisions (3 months)
—
Valuation
0.0/10The company loses money, so no valuation multiple can be read: a negative P/E is not a discount.
P/E (TTM)
—
N/A (loss)
Sector 11.0x|S&P 22.1x
Forward P/E (adjusted)
—
N/A (loss)
EV / EBITDA
—
N/A (loss)
Sector 16.5x|S&P 14.9x
PEG
—
Sector 0.38|S&P 0.84
Market cap
238M USD
Financial strength
10.0/10Cash covers 1941.9% of the debt, no net debt (net cash).
Net debt / EBITDA
—
Gearing (net debt / equity)
-110.93%
Net cash
Cash
125M USD
Cash / market cap
52.66%
Very solid
Cash / total debt
1941.89%
Net cash
Net debt
-119M USD
Equity
107M USD
Closed daily candles, 2 years
Last close on November 20, 2026: 3.79 USD
- MM203.92
- MM503.82
- MM2004.21
- RSI 1447.7
Top panel: closed candles, 20, 50 and 200-day moving averages, with volume in grey. Bottom panel: 14-day RSI with dashed 30 and 70 levels.
200-day average slope, 1 month
-1.99%
200-day average slope, 3 months
-6.16%
50-day average slope, 1 month
-5.36%
Price structure
Lower lows
Bullish RSI divergence
No
20-day volatility
6.18 % per day
Volatility change
+16.07%
Forecasts by fiscal year
| Fiscal year | EPS | Normalised EPS | Revenue | EBITDA | Net income |
|---|---|---|---|---|---|
| 2026 | -1.32 (10) | -1.21 (3) | 7 (10) | -100 (1) | -90 (9) |
| 2027 | -0.74 (10) | -0.84 (4) | 6 (9) | -90 (1) | -65 (9) |
Amounts in millions of USD, EPS in USD per share. In brackets, the number of analysts. Consensus as of November 11, 2026.
Same sub-industry: 797 companies behind the medians.
| # | Company | Code | Country | Overall / 10 | Fundamentals / 10 | Mkt cap | P/E | Net margin | Revenue growth | ROIC | Net debt / EBITDA | FCF yield | 1-year perf. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ALERS | 4.5 | 4.5 | 284M USD | 36.9x | 4.2 % | 9.1 % | 3.7 % | -0.1x | 2.0 % | 8.2 % | ||
| 2 | BNTC | 4.0 | N/A | 286M USD | Not meaningful (loss) | — | — | -37.5 % | 3.2x | -6.2 % | -40.5 % | ||
| 3 | CAMP | 3.8 | 3.5 | 238M USD | Not meaningful (loss) | -2276.3 % | 138.9 % | -139.5 % | — | -11.1 % | 0.3 % | ||
| 4 | SPRY | 2.7 | 3.0 | 298M USD | Not meaningful (loss) | -163.6 % | 16.0 % | -112.7 % | 0.1x | -61.5 % | -59.0 % | ||
| 5 | 7630 | 2.7 | 2.7 | 292M USD | Not meaningful (loss) | -213.6 % | 14.1 % | -60.5 % | 5.4x | -4.8 % | -77.2 % | ||
| 6 | 4894 | 2.1 | 1.5 | 296M USD | Not meaningful (loss) | -1478.4 % | -52.6 % | -15.8 % | 5.0x | — | -13.8 % | ||
| 7 | EVMN | 2.1 | 0.9 | 291M USD | Not meaningful (loss) | — | -100.0 % | -68.1 % | 1.3x | -31.3 % | -63.4 % | ||
| 8 | 6945 | 1.5 | N/A | 287M USD | Not meaningful (loss) | — | — | -22.4 % | 4.5x | -4.1 % | -7.9 % | ||
| 9 | 2617 | 1.5 | N/A | 294M USD | Not meaningful (loss) | -738.1 % | — | -36.0 % | 3.6x | -12.3 % | -96.8 % |
